Drug Profile
Ad5.F35 hGCC PADRE
Alternative Names: Ad5 GUCY2C PADRE; Ad5 hGCC PADRE; Ad5.F35-hGCC-PADRE; GCC cancer vaccineLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator InnobationBio; Thomas Jefferson University
- Developer Targeted Diagnostics and Therapeutics; Thomas Jefferson University; Unknown
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Preclinical Gastrointestinal cancer
Most Recent Events
- 06 Dec 2022 Deal created
- 06 Dec 2022 Liminatus Pharma and Iris Acquisition agree to co-develop Ad5.F35 hGCC PADRE for colorectal, pancreatic, gastric, and esophageal cancers
- 02 Dec 2022 Preclinical trials in Gastrointestinal cancer in USA (IM), prior to December 2022 (Liminatus Pharma website, December 2022)